This study will help identify chemicals made by the body that can be used as “markers” (measures) of certain kidney proteins that transport drugs into the kidney.
This study will consist of two parts and an optional third part, each with two arms. During Part 1 Arm A, you will receive a single dose of the drug metformin. During Part 1 Arm B, you will receive a single dose of the drug cimetidine, then one hour later, a single dose of metformin. During Part 2 Arm A, you will receive a single dose of the drug furosemide. During Part 2 Arm B, you will receive a single dose of the drug probenecid, then one hour later, a single dose of furosemide. During Part 3 Arm A, you will receive a single dose of the drug metformin. During Part 3 Arm B, you will receive a single dose of dolutegravir, then one hour later, a single dose of metformin. Blood will be drawn from an intravenous line following administration of the study drug(s). Urine samples will also be collected. You will receive a screening medical exam and will undergo routine blood and urine laboratory tests.
You will receive
- up to $675 for completing only Part 1
- up to $675 for completing only Part 2
- up to $675 for completing only Part 3
You may be eligible to take part in this study if you
- Are from 18-65 years old and healthy
- Are not taking any medications (prescription and non-prescription) or dietary/herbal supplements that can interfere with your ability to eliminate the study drugs from your body
- Are willing to stop taking dietary/herbal supplements and citrus juices for several weeks
- Are willing to stop consuming caffeinated beverages or other caffeine-containing products the evening before and the morning of the first day of each study arm
- Are willing to stop drinking alcoholic beverages for at least 1 day prior to any study day and during the study day
- Arewilling to use an acceptable method of birth control that does not include oral contraceptive pills or patches (such as abstinence, copper IUD, condom) throughout your participation in the study and for at least 3 weeks after you last take the study drugs
- Have the time to participate
You will not be eligible to take part in this study if you
- Are under 18 or over 65 years old
- Smoke/vape/chew tobacco products
- Use cannabis products, including marijuana, hemp, and other THC- or CBD-containing products
- Are taking medications or dietary/herbal supplements that can interfere with your ability to eliminate the study drugs from your body
- Have a chronic illness such as (but not limited to) kidney disease, liver disease, diabetes mellitus, high blood pressure, coronary artery disease, chronic obstructive pulmonary disease, cancer, or HIV/AIDS
- Have a hematologic (blood) disorder
- Have a history of drug or alcohol addiction or major psychiatric illness
- Have a history of allergy to metformin, cimetidine, furosemide, probenecid, or dolutegravir
- Are pregnant, nursing, or plan to become pregnant within 3 weeks after participation
The Washington State University College of Pharmacy and Pharmaceutical Sciences is conducting this research study through funding provided by the National Institutes of Health.
For more information about this study, please contact:
Deena Hadi, Program Manager
Phone: (509) 368-6692
Email: deena.hadi@wsu.edu
The WSU Institutional Review Board has reviewed and approved this research project for human subject participation.
